Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate
Authors:
- 1 April 2010
- journal article
- clinical trial
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 64 (4) , 271-274
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Bisphosphonates in the treatment of thalassemia-associated osteoporosisJournal of Endocrinological Investigation, 2008
- Taurine increases cell proliferation and generates an increase in [Mg2+]i accompanied by ERK 1/2 activation in human osteoblast cellsFEBS Letters, 2007
- Reduction of plasma taurine level in children affected by Osteogenesis Imperfecta during bisphosphonate therapyBiomedicine & Pharmacotherapy, 2007
- Taurine promotes connective tissue growth factor (CTGF) expression in osteoblasts through the ERK signal pathwayAmino Acids, 2006
- Taurine Analogues; A New Class of Therapeutics: Retrospect and ProspectsCurrent Medicinal Chemistry, 2005
- Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled StudyJournal of Bone and Mineral Research, 2005
- Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosisBone, 2003
- The Inhibitory Effect of Alendronate and Taurine on Osteoclast Differentiation Mediated by Porphyromonas gingivalis Sonicates In VitroJournal of Endodontics, 2003
- Intravenous Neridronate in Adults With Osteogenesis ImperfectaJournal of Bone and Mineral Research, 2003
- The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfectaJournal of Clinical Investigation, 2002